Poor
Poorly Aligned
Patient Risk:
High
Summary
Overall alignment is poor due to significant safety and dosing omissions and multiple unsupported or non-label claims. Some label-supported statements (mechanism, lipid-lowering effect, and grapefruit interaction) are present, but key safety information (pregnancy contraindication, pediatric use, dosing safety, alcohol cautions, and myopathy risk with interactions) is missing, and several red wine claims are not supported by the label.
Category Scores
Accurate Statements
Lipitor, also known as Atorvastatin, is a statin medication.
12.1
Lipitor lowers cholesterol levels in the blood.
12.1, 12.2
Lipitor belongs to a class of drugs known as HMG-CoA reductase inhibitors.
12.1
Lipitor works by inhibiting the production of cholesterol in the liver.
12.1
Grapefruit juice interacts with Lipitor, increasing the risk of muscle damage and other side effects.
7.2, 7
Lipitor reduces the risk of cardiovascular events (lipid-lowering therapy reducing CV risk).
12.1
Unsupported Statements
Lipitor reduces the risk of stroke.
Label does not explicitly claim stroke risk reduction for atorvastatin in the provided sections.
There is no known interaction between red wine and Lipitor.
Label does not state no interaction with red wine.
Grapefruit juice contains furanocoumarins, which can inhibit the enzyme responsible for metabolizing Lipitor.
Label does not describe furanocoumarins.
FDA recommends that patients taking Lipitor avoid consuming large amounts of grapefruit or grapefruit juice.
Label does not specify 'large amounts'; it notes grapefruit interaction but exact phrasing about 'large amounts' is not present in the provided sections.
Moderate red wine consumption (1-2 glasses per day) did not significantly affect Lipitor levels in the blood.
Label does not address red wine interactions explicitly.
The study concluded that red wine can be safely consumed in moderation by patients taking Lipitor.
Label does not include such study conclusions.
According to DrugPatentWatch.com, there are no known interactions between red wine and Lipitor.
Label does not cite external sources; not a labeling claim.
Dr. James E. Dalen notes that the interaction between red wine and Lipitor is minimal.
Not a labeling claim.
Lipitor and red wine can be safely consumed together in moderation.
Not a labeling claim.
Drinking red wine while taking Lipitor is allowed in moderation (1-2 glasses per day).
Not a labeling claim.
Red wine will not affect Lipitor levels (per Journal of Cardiovascular Medicine study).
Not a labeling claim.
Grapefruit juice should be avoided while taking Lipitor.
Label phrasing provided does not explicitly state 'should be avoided'; the available grapefruit information is about interaction, not an explicit 'avoid' directive in the cited sections.
Contradictions
Important Omissions
Pregnancy contraindication and Fetal risk with statins (contraception for women of childbearing potential).
Importance:
High
Pediatric safety and dosing for certain ages/conditions.
Importance:
Medium
Dosing ranges and maximum doses (e.g., up to 80 mg daily) and hepatic impairment adjustments.
Importance:
High
Alcohol-related safety and liver injury cautions.
Importance:
Medium
Myopathy/rhabdomyolysis risk with drug interactions and liver disease.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Major safety information and dosing considerations are omitted; several high-risk interactions and population-specific cautions are not addressed.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Significant safety and dosing omissions; unsupported and non-label claims about red wine and stroke risk; mischaracterization of grapefruit interactions.
Suggested Improvement
Restrict claims to label-supported statements; explicitly include pregnancy contraindication, pediatric use, dosing ranges, hepatic impairment considerations, and alcohol-related cautions; remove unsubstantiated red wine recommendations and ensure grapefruit interaction statements reflect labeling language.